Herantis Pharma Plc’s Financial Statements Release January 1 - December 31, 2019
Looking forward to read-outs of fully recruited clinical studiesHerantis Pharma PlcCompany release, insider information 27 February 2020 at 5:00 PM Eastern European Time Highlights in January-December 2019: · Herantis Pharma (“Herantis” or “Company”) completed a successful directed share issue in March. · Phase 2 clinical study with Lymfactin® in the treatment of breast cancer associated lymphedema expanded in March in two university hospitals in Sweden. · Herantis announced in April 12-month follow-up review from its Phase 1 clinical study of Lymfactin®. · Herantis